| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = -$363,429 ) |
| | 2025 | 2023 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA043476 | Buprenorphine for probationers and parolees: Bridging the gap into treatment | 000 | 5 | NIH | 10/1/2024 | -$117,932 |
| | 2025 | 2023 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | UG1DA050077 | Long-acting naltrexone for pre-release prisoners: A randomized trial of mobile treatment | 000 | 5 | NIH | 10/1/2024 | -$245,497 |
|
| Issue Date FY: 2024 ( Subtotal = $6,425,291 ) |
| | 2024 | 2024 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA056888 | Optimizing PrEP Implementation and Cost-effectiveness among Sexual and Gender Minority Individuals with a Substance Use Disorder | 000 | 3 | NIH | 6/21/2024 | $912,089 |
| | 2024 | 2024 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R34DA059770 | Addressing racial disparities in opioid overdose deaths using an open source peer recovery coach training and multimodal mobile health platform | 000 | 1 | NIH | 6/27/2024 | $225,981 |
| | 2024 | 2024 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R34DA059770 | Addressing racial disparities in opioid overdose deaths using an open source peer recovery coach training and multimodal mobile health platform | 001 | 1 | NIH | 8/21/2024 | -$225,981 |
| | 2024 | 2024 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R34DA059770 | Addressing racial disparities in opioid overdose deaths using an open source peer recovery coach training and multimodal mobile health platform | 001 | 1 | NIH | 8/21/2024 | $225,981 |
| | 2024 | 2024 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA057685 | Addressing substance use among the social networks of suspected drug overdose decedents: rapidly translating epidemiology into prevention intervention science | 000 | 1 | NIH | 9/6/2024 | $157,603 |
| | 2024 | 2024 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA058674 | A comparative effectiveness trial of sublingual versus extended-release buprenorphine with individuals leaving a carceral setting | 001 | 2 | NIH | 5/24/2024 | $1,086,043 |
| | 2024 | 2024 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA056287 | Comparative- and cost-effectiveness research determining the optimal intervention for advancing transgender women living with HIV to full viral suppression | 000 | 2 | NIH | 6/17/2024 | $896,441 |
| | 2024 | 2024 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R34DA059770 | Addressing racial disparities in opioid overdose deaths using an open source peer recovery coach training and multimodal mobile health platform | 002 | 1 | NIH | 8/27/2024 | $0 |
| | 2024 | 2024 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R34DA055532 | Intervention to Reduce Internalized Stigma (IRIS) among People Living with HIV who use Substances | 000 | 3 | NIH | 7/5/2024 | $236,463 |
| | 2024 | 2024 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA057052 | Scope and impact of methadone take-home and telehealth practice changes during the COVID-19 pandemic | 000 | 3 | NIH | 6/17/2024 | $682,722 |
| | 2024 | 2024 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | UG3DA058305 | Continuing Care App for Justice-Involved Individuals with Substance Use Disorders | 001 | 2 | NIH | 5/17/2024 | $555,180 |
| | 2024 | 2024 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA045724 | Opioid Use Disorder Treatment Linkage at STD Clinics using Buprenorphine (OUTLAST-B) | 001 | 5 | NIH | 4/25/2024 | $55,985 |
| | 2024 | 2024 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA045724 | Opioid Use Disorder Treatment Linkage at STD Clinics using Buprenorphine (OUTLAST-B) | 000 | 5 | NIH | 1/8/2024 | $503,863 |
| | 2024 | 2024 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R18HS029783 | Leveraging social determinants via artificial intelligence and peer coaching to address racial disparities in primary care among people who use opioids | 003 | 3 | AHRQ | 8/23/2024 | $564,435 |
| | 2024 | 2023 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA043476 | Buprenorphine for probationers and parolees: Bridging the gap into treatment | 000 | 5 | NIH | 4/4/2024 | $0 |
| | 2024 | 2023 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA058674 | A comparative effectiveness trial of sublingual versus extended-release buprenorphine with individuals leaving a carceral setting | 000 | 1 | NIH | 2/2/2024 | $0 |
| | 2024 | 2023 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | UG1DA050077 | Long-acting naltrexone for pre-release prisoners: A randomized trial of mobile treatment | 001 | 5 | NIH | 9/19/2024 | $0 |
| | 2024 | 2023 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | UG1DA050077 | Long-acting naltrexone for pre-release prisoners: A randomized trial of mobile treatment | 000 | 5 | NIH | 5/9/2024 | $0 |
| | 2024 | 2023 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | UG3DA058305 | Continuing Care App for Justice-Involved Individuals with Substance Use Disorders | 000 | 1 | NIH | 10/23/2023 | $0 |
| | 2024 | 2023 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R61DA059033 | Implementing a patient navigation intervention across a health system to address treatment entry inequities | 000 | 1 | NIH | 12/8/2023 | $0 |
| | 2024 | 2023 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R18HS029783 | Leveraging social determinants via artificial intelligence and peer coaching to address racial disparities in primary care among people who use opioids | 001 | 2 | AHRQ | 5/10/2024 | $548,486 |
| | 2024 | 2022 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA045562 | Getting Off: A Theory-based mHealth Intervention for Methamphetamine-using MSM | 000 | 5 | NIH | 8/20/2024 | $0 |
| | 2024 | 2022 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA057608 | Treating Polysubstance Use in Methadone Maintenance: Application of Novel Digital Technology | 000 | 1 | NIH | 9/19/2024 | $0 |
| | 2024 | 2021 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | U01DA046910 | Facilitating the Implementation of Interim Methadone to Increase Treatment Access: A Multi-Site Implementation Trial | 000 | 4 | NIH | 11/29/2023 | $0 |
| | 2024 | 2021 | FRIENDS RESEARCH INSTITUTE, INC. | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA040636 | Long-acting naltrexone for pre-release prisoners: A randomized trial of mobile treatment | 000 | 5 | NIH | 4/8/2024 | $0 |
| | 2024 | 2020 | FRIENDS RESEARCH INSTITUTE, INC | 1040 PARK AVE STE 103 | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R21DA047580 | People Preferring Fentanyl (PPF): Characteristics, Outcomes, and Perspectives | 000 | 2 | NIH | 1/23/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $8,708,120 ) (Continued on the next page) |
| | 2023 | 2023 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R61DA059033 | Implementing a patient navigation intervention across a health system to address treatment entry inequities | 000 | 1 | NIH | 9/21/2023 | $946,763 |
| | 2023 | 2023 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA056287 | Comparative- and cost-effectiveness research determining the optimal intervention for advancing transgender women living with HIV to full viral suppression | 000 | 1 | NIH | 8/11/2023 | $636,993 |
| | 2023 | 2023 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA045724 | Opioid Use Disorder Treatment Linkage at STD Clinics using Buprenorphine (OUTLAST-B) | 000 | 4 | NIH | 1/30/2023 | $688,020 |
| | 2023 | 2023 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA058674 | A comparative effectiveness trial of sublingual versus extended-release buprenorphine with individuals leaving a carceral setting | 000 | 1 | NIH | 9/15/2023 | $881,830 |
| | 2023 | 2023 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | UG3DA058305 | Continuing Care App for Justice-Involved Individuals with Substance Use Disorders | 000 | 1 | NIH | 5/15/2023 | $573,506 |
| | 2023 | 2023 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA057052 | Scope and impact of methadone take-home and telehealth practice changes during the COVID-19 pandemic | 001 | 2 | NIH | 6/29/2023 | $628,884 |
| | 2023 | 2023 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R34DA055532 | Intervention to Reduce Internalized Stigma (IRIS) among People Living with HIV who use Substances | 001 | 2 | NIH | 8/1/2023 | $275,802 |
| | 2023 | 2023 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R21MH130271 | Development and Testing of an Identity Measure for Transgender and Gender Diverse Persons | 001 | 2 | NIH | 8/22/2023 | $193,686 |
| | 2023 | 2023 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA056888 | Optimizing PrEP Implementation and Cost-effectiveness among Sexual and Gender Minority Individuals with a Substance Use Disorder | 001 | 2 | NIH | 7/27/2023 | $908,730 |
| | 2023 | 2023 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | UG1DA050077 | Long-acting naltrexone for pre-release prisoners: A randomized trial of mobile treatment | 002 | 5 | NIH | 9/14/2023 | -$444,092 |
| | 2023 | 2023 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | UG1DA050077 | Long-acting naltrexone for pre-release prisoners: A randomized trial of mobile treatment | 002 | 5 | NIH | 9/14/2023 | $444,092 |
| | 2023 | 2023 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | UG1DA050077 | Long-acting naltrexone for pre-release prisoners: A randomized trial of mobile treatment | 000 | 5 | NIH | 4/28/2023 | $1,967,149 |
| | 2023 | 2023 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | UG1DA050077 | Long-acting naltrexone for pre-release prisoners: A randomized trial of mobile treatment | 001 | 5 | NIH | 5/1/2023 | $444,092 |
| | 2023 | 2023 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA043476 | Buprenorphine for probationers and parolees: Bridging the gap into treatment | 000 | 5 | NIH | 4/20/2023 | $562,665 |
| | 2023 | 2022 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA057052 | Scope and impact of methadone take-home and telehealth practice changes during the COVID-19 pandemic | 000 | 1 | NIH | 12/23/2022 | $0 |
| | 2023 | 2022 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA057608 | Treating Polysubstance Use in Methadone Maintenance: Application of Novel Digital Technology | 000 | 1 | NIH | 1/27/2023 | $0 |
| | 2023 | 2022 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R34DA055532 | Intervention to Reduce Internalized Stigma (IRIS) among People Living with HIV who use Substances | 000 | 1 | NIH | 11/17/2022 | $0 |
| | 2023 | 2022 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R21MH130271 | Development and Testing of an Identity Measure for Transgender and Gender Diverse Persons | 000 | 1 | NIH | 12/28/2022 | $0 |
| | 2023 | 2022 | FRIENDS RESEARCH INSTITUTE INC | 1040 PARK AVE | BALTIMORE | MD | 21201-5633 | BALTIMORE CITY | USA | R01DA056888 | Optimizing PrEP Implementation and Cost-effectiveness among Sexual and Gender Minority Individuals with a Substance Use Disorder | 000 | 1 | NIH | 11/17/2022 | $0 |
|
